by admin | May 17, 2022 | News
CEO Ana Slipicevic present the MTHFD2 program and one-carbon therapeutics AB in the Hot Topic session at Bio€quity 2022 in Milan.
by admin | May 12, 2022 | News
The MTHFD2 program is pitched by CEO Dr Ana Slipicevic at the Meet2Win conference in Bordeaux and wins a pitch price!
by admin | Mar 29, 2022 | News
One-carbon therapeutics AB is granted 3,000,000 SEK from Sweden’s innovation agency Vinnova under the Medtech4Health and SweLife programs for further development of the MTHFD2 program.
by admin | Mar 6, 2022 | News
We are proud that the MTHFD2 inhibitors are now published in the prestigious journal Nature Cancer. In this first report, we describe that MTHFD2 inhibitors deplete cells of thymidine, specifically in cancer cells. We show that the loss of thymidine causes replication...
by admin | Feb 1, 2022 | News
We are very pleased to announce that Dr Ana Slipicevic has been appointed as acting CEO of one-carbon therapeutics AB. Ana is joining us from Oncopeptides AB where she has been translational research director and leading a team developing and implementing...
